- Home
- ORRF vs ACRS Comparison
ORRF vs ACRS Comparison
Compare ORRF & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ORRF | ACRS |
|---|---|---|
| Founded | 1919 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 791.0M | 868.5M |
| IPO Year | 1995 | 2015 |
Fundamental Metrics
Financial Performance| Metric | ORRF | ACRS |
|---|---|---|
| Price | $42.60 | $5.48 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $42.00 | $10.20 |
| AVG Volume (30 Days) | 68.9K | ★ 1.9M |
| Earning Date | 04-21-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.29% | N/A |
| EPS Growth | ★ 182.43 | 69.01 |
| EPS | ★ 2.21 | N/A |
| Revenue | ★ $37,144,000.00 | $1,683,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.15 | $4.24 |
| P/E Ratio | $19.16 | ★ N/A |
| Revenue Growth | ★ 36.00 | N/A |
| 52 Week Low | $31.88 | $1.74 |
| 52 Week High | $43.81 | $6.60 |
Technical Indicators
Market Signals| Indicator | ORRF | ACRS |
|---|---|---|
| Relative Strength Index (RSI) | 52.22 | 45.15 |
| Support Level | $40.97 | $4.13 |
| Resistance Level | $42.48 | $5.87 |
| Average True Range (ATR) | 0.79 | 0.34 |
| MACD | 0.00 | -0.11 |
| Stochastic Oscillator | 62.55 | 32.87 |
Price Performance
Historical ComparisonAbout ORRF Orrstown Financial Services Inc
Orrstown Financial Services Inc is a financial holding company. Through its subsidiaries, it operates in the community banking segment and engages in lending activities, including commercial, residential, commercial mortgages, construction, municipal, and various forms of consumer lending and deposit services, including checking, savings, time, and money market deposits. The Group also provides fiduciary, investment advisory, insurance, and brokerage services. It offers services to individuals, professionals, small businesses, and other enterprises across different locations in the United States through its branch network and client service centers.
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.